A New Approach to the Treatment of Metastatic Paraganglioma: Sorafenib


GUNALDI M., KARA İ. O. , DUMAN B. B. , AFSAR C. U. , ERGIN M. , AVCI A.

CANCER RESEARCH AND TREATMENT, cilt.46, ss.411-414, 2014 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 46 Konu: 4
  • Basım Tarihi: 2014
  • Doi Numarası: 10.4143/crt.2013.093
  • Dergi Adı: CANCER RESEARCH AND TREATMENT
  • Sayfa Sayısı: ss.411-414

Özet

Paragangliomas are relatively rare chromaffin cell tumors which may be cured through resection. Patients with paragangliomas may develop metastatic diseases. There is no consensus regarding refractory chemotherapy for treatment of metastatic disease. In this report, we presented a case of a 43-year-old woman who was admitted to the hospital with a history of episodic headaches, diaphoresis, and weakness. Elevated plasma catecholamine levels and a right paraaortic mass were observed on computed tomography. The mass was excised, and a diagnosis of paraganglioma was confirmed. After 20 months of follow-up, local recurrence and metastases were detected in the thorax, abdomen, and skeletal system. Plasma and urinary catecholamine levels were high. Chemotherapy was administered, and no improvement was observed. Therefore, following this palliative conventional chemotherapy, sorafenib was administered for three months, and, finally, positron emission tomography showed that the patient's lesions had completely regressed.